-- HAV remained patent and host-cell remodeling was observed in non-human primate model -- -- Preclinical study represents milestone in the development of small-diameter HAVs for use in cardiac bypass surgery -- -- Results presented at Advanced Therapies Week 2022 -- DURHAM, N.C., Jan....
DURHAM, N.C., Jan. 06, 2022 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissue at commercial scale, today announced that results from the first series of compassionate use cases of...
DURHAM, N.C., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissue at commercial scale, today announced the first preclinical results of the use of Humacyte’s Human Acellular...
DURHAM, N.C., Dec. 31, 2021 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissue at commercial scale, today announced the appointment of Surgical Key Opinion Leaders (KOLs) Alan P....
-- Vanderbilt University Medical Center patient received the HAV under the U.S. Food and Drug Administration’s (FDA) Expanded Access Program (EAP) in April 2019 -- -- After replacement, the patient resumed regular physical activity with no signs of infection of the HAV implant observed -- --...
-- Patency and host cell remodeling of the HAV were observed in all study implants – -- Preclinical study is one component of Humacyte’s expansion of the testing of the HAV in a broader cardiac bypass surgery application – DURHAM, N.C., Nov. 16, 2021 (GLOBE NEWSWIRE) -- Humacyte, Inc....
– Performance of HAVs produced in the LUNA200™ commercial-scale system demonstrated efficacy that is similar to prior HAV performance in dialysis access trials – – 83% secondary patency observed at 12 months post-implantation – – Data presented today in keynote presentation at 6th World Congress...
-- Completed business combination with Alpha Healthcare Acquisition Corp. and raised $242M in proceeds -- -- Progressed advanced-stage clinical- and early-stage programs of the human acellular vessel (HAV™) and other engineered tissue platform applications -- DURHAM, N.C., Nov....
DURHAM, N.C., Nov. 09, 2021 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissue at commercial scale, today announced that Laura Niklason, M.D., Ph.D., Chief Executive Officer, will present...
DURHAM, N.C., Nov. 08, 2021 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissue at commercial scale, today announced that leadership will present new data and additional information on its...
